menu
    • menu
    [{"orgOrder":0,"company":"Grand Pharma","sponsor":"Grand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"Integrin alpha-IIb\/beta-3","graph1":"Neurology","graph2":"Phase IV","graph3":"Grand Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grand Pharma \/ Grand Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Grand Pharma \/ Grand Pharma"},{"orgOrder":0,"company":"Grand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Grand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"STC3141","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grand Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Grand Pharma

    Menu

    Grand Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STC3141

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Grand Pharma’s STC3141 Meets Phase II Endpoint in China for First Time

                            Details : STC3141 is the first investigational sepsis treatment program is centered on rebuilding immune homeostasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : STC3141

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : Beijing Tiantan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

                            Details : Tirofiban HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Branch Atheromatous Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : Beijing Tiantan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Grand Pharma

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

                            Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 12, 2022

                            Lead Product(s) : Tirofiban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth